Long-term versus short-term doxycycline for C. trachomatis-reactive arthritis
This article has no abstract so we have provided the first paragraph of the full text.
Urogenital infection with Chlamydia trachomatis is a major cause of reactive arthritis. Short-term antibiotics are administered to patients with C. trachomatis-reactive arthritis; however, these are often ineffective in altering the course of established disease. Putschky and colleagues have now performed a randomized, double-blind, placebo-controlled trial to assess the safety and efficacy of long-term versus short-term doxycycline treatment for C. trachomatis-reactive arthritis.
Full text of this article is available with one of the following:
- Personal subscription Purchase your own personal subscription to this journal. Already a subscriber? Please log in for immediate access.
- 7 day single article pass for US$18 In order to purchase this article you must be a registered user. Please register or log in.
- Site licence Learn more about institutional site licences
Current Subscribers
Please log in to access the full text article using the login box at the top of the page.
MORE ARTICLES LIKE THIS
These links to content published by NPG are automatically generated.
